Connect to other sites within the UBM Medica Network
The HPV 16/18 vaccine protects women from cervical, anal, and oral HPV infections that can lead to cancer, including some women previously exposed to HPV. Image © Jes2u.photo / Shutterstock.com.
Pembrolizumab Effective in Metastatic Head and Neck Cancer
Pembrolizumab demonstrated a 24.8% overall response rate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Elective Dissection of Lymph Nodes Improves Survival in Early Oral Cancer
Elective neck lymph node surgery for patients with early oral cancer reduces the risk of cancer recurrence and improves survival.
Surveillance Compliance Improves Head and Neck Cancer Survival
A new study found that compliance with post-treatment clinical surveillance improved survival outcomes in patients with head and neck squamous cell carcinoma.
Increased Risk of Second Malignancies With Radioactive Iodine Therapy for Thyroid Cancer
A new population-based study has found that patients with thyroid cancer who are treated with radioactive iodine therapy are at increased risk for developing salivary cancer as a second malignancy.
HPV Vaccine Can Protect Previously Exposed Patients
The HPV 16/18 vaccine protects women from cervical, anal, and oral HPV infections that can lead to cancer, including some women previously exposed to HPV.
Vaccinating Boys Against HPV Proves Cost-Effective
Vaccinating boys aged 12 years against the human papillomavirus (HPV) may be cost-effective in the prevention of oropharyngeal cancer.
Older Men at Higher Risk of Persistent Oral HPV Infection
An infection with oral HPV16 is likely to last for a year or longer in older men, putting them at higher risk for the development oropharyngeal cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.